![PDF) Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK PDF) Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK](https://i1.rgstatic.net/publication/332655014_Cost-Effectiveness_Analysis_of_Fulvestrant_500_mg_in_Endocrine_Therapy-Naive_Postmenopausal_Women_with_Hormone_Receptor-Positive_Advanced_Breast_Cancer_in_the_UK/links/5cc1f1c9a6fdcc1d49aef41d/largepreview.png)
PDF) Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
![PDF) Lipoprotein(a) and the risk of cardiovascular disease in the European population: Results from the BiomarCaRE consortium PDF) Lipoprotein(a) and the risk of cardiovascular disease in the European population: Results from the BiomarCaRE consortium](https://i1.rgstatic.net/publication/316552385_Lipoproteina_and_the_risk_of_cardiovascular_disease_in_the_European_population_Results_from_the_BiomarCaRE_consortium/links/59ef4c20458515ec0c7b5aaf/largepreview.png)
PDF) Lipoprotein(a) and the risk of cardiovascular disease in the European population: Results from the BiomarCaRE consortium
![PDF) Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects PDF) Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects](https://i1.rgstatic.net/publication/315704361_Effect_of_Semaglutide_on_the_Pharmacokinetics_of_Metformin_Warfarin_Atorvastatin_and_Digoxin_in_Healthy_Subjects/links/58ebdc1fa6fdcc0dcecc40ca/largepreview.png)